Krop Julie sold $125K of AQST
Krop Julie sold 25,000 shares of Aquestive Therapeutics, Inc. (AQST) at $5.02 ($0.13M total) on 2026-06-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale details (25,000 shares; $125,392.50 total) executed on 2026-06-23 under a 10b5-1 plan; no operational or financial updates are provided.
Market read
Useful for monitoring insider activity/flow, but it does not introduce new fundamentals that would typically drive a sustained repricing.
What to watch
Traders may miss that the director has 0 shares after the sale, which can slightly increase perceived insider alignment risk even if the plan is scheduled.
Background
The article is an SEC Form 4 insider transaction disclosure for Aquestive Therapeutics, Inc. (AQST).
Ticker impact
Aquestive Therapeutics (AQST) disclosed via Form 4 that director Krop Julie sold 25,000 shares at $5.0157 on 2026-06-23 under a 10b5-1 plan.
Likely limited immediate impact; any effect is more sentiment/flow-related than fundamental.
The filing is a scheduled open-market sale with a pre-arranged 10b5-1 plan and the director ends with 0 shares, but no new company fundamentals (earnings, guidance, trials, deals) are disclosed.
Market effects
Minimal; this is company-specific insider liquidity with no sector-wide regulatory/clinical catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be largely non-informational and should not be over-weighted versus other catalysts.
Key entities
- issuerAquestive Therapeutics, Inc.
Subject of the Form 4 insider transaction; director Krop Julie sold shares under a 10b5-1 plan.
- insiderKrop Julie
Director who executed the reported open-market sale and ended with 0 shares.
